Molecular diagnostics-focused Nanogen (San Diego, Calif.) has entered an agreement to combine with the privately held Elitech Group (Paris, France) in an all-stock deal valued at approximately $98 million. With estimated first-year revenues of $150 million, the combined company will encompass molecular and point-of-care diagnostics as well as clinical chemistry and molecular biology. Structured as a reverse acquisition of Nanogen by Elitech, the deal has been approved by the boards of both companies and is expected to close by the end of the first quarter of 2009.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

October 2008 - Table of Contents

DTTR October 2008 (full PDF issue)

Myriad Genetics May Spin Off Pharma Business

FDA Clears Third IVDMIA: XDx’s AlloMap

Nanogen to Merge With French Diagnostics Company

Meridian Bioscience Inks Canadian Distribution Deal

Inside the Diagnostics Industry: Nanogen’s David Ludvigson on Mergers, Markets, and Microarrays

New Gene Variant Linked to Prostate Cancer Risk

Protein Variant Predicts Chemotherapy Response

Pathwork Diagnostics Raises $20 Million

Pall Corporation Acquires GeneSystems

Physicians Frustrated by CMS’s Quality Reporting Initiative Feedback

IVD Stocks Down 6%; OraSure, Luminex Only Gainers

Biomarker for Soft Tissue Sarcoma